GILD
Gilead Sciences, Inc.
Healthcare · Drug Manufacturers - General · United States · Stock
Score Breakdown
Scored for Aggressive Growth profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- A perfect profitability score was supported by a 28.9% net margin, 34.0% operating margin, and 14.4% return on assets in FY2025, forming the strongest pillar of the composite score.
- A near-perfect momentum score reflected sustained high operating and net income across the trailing four quarters, with operating income remaining above $1,984,000,000 in every period.
- Consistent multi-year dividend growth from $2.92 in FY2022 to $3.16 in FY2025 at a moderate 47.0% payout ratio contributed positively to the income-oriented component of the score.
Why Not Higher
- Revenue growth of only +2.4% in FY2025 tempered the growth score from a perfect mark, as the top-line expansion lagged the dramatic bottom-line recovery.
- The Biotech & Genomics theme assignment did not translate into any score contribution under the model's current methodology, leaving meaningful potential points unrealized.
Data Confidence
10 / 10
Very High — full data coverage
Why This Score
Grounded in figures from this company's SEC EDGAR filings — not a restatement of the score itself.
Revenue grew modestly from FY2024 to FY2025, rising +2.4% to $29,443,000,000. However, net income surged from $480,000,000 in FY2024 to $8,510,000,000 in FY2025 (+1,672.9%), and diluted EPS rose from $0.38 in FY2024 to $6.78 in FY2025 (+1,684.2%).
The model rewarded the dramatic bottom-line recovery in FY2025, while the relatively modest top-line expansion of +2.4% likely tempered the score from a perfect mark.
In FY2025, Gilead posted a net margin of 28.9%, an operating margin of 34.0%, and a return on assets of 14.4%.
These metrics reflect broad-based profitability strength across income and asset efficiency dimensions, which the model rewarded with a perfect score.
Filing evidence currently available does not support a more specific explanation for this factor.
Revenue across the last four quarters was $7,082,000,000 in 2025Q2, $7,769,000,000 in 2025Q3, $7,925,000,000 in 2025Q4, and $6,960,000,000 in 2026Q1, showing a build through Q4 followed by a pullback. Net income similarly peaked at $3,052,000,000 in 2025Q3 before settling to $2,021,000,000 in 2026Q1, while operating income remained elevated, reaching $3,327,000,000 in 2025Q3 and $2,586,000,000 in 2026Q1.
The model recognized a sustained high level of earnings and operating income across the trailing four quarters, with only a moderate sequential decline in the most recent period, supporting a near-perfect momentum score.
Dividends per share have grown steadily from $2.92 in FY2022 to $3.00 in FY2023, $3.08 in FY2024, and $3.16 in FY2025. The dividend payout ratio in FY2025 stood at 47.0%.
The model recognized a consistent multi-year dividend growth trend alongside a moderate payout ratio, reflecting a balance between returning capital to shareholders and retaining earnings, though the score fell short of the maximum, likely reflecting the payout ratio level relative to peers.
Gilead Sciences is assigned to the Biotech & Genomics macro theme.
Although the Biotech & Genomics theme is assigned, this assignment did not translate into a score under the model's current methodology for this factor.
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Gilead Sciences delivered a dramatic earnings recovery in FY2025, with net income surging +1,672.9% to $8,510,000,000 and diluted EPS rising from $0.38 to $6.78, even as revenue grew modestly +2.4% to $29,443,000,000. Profitability metrics were exceptional, with a net margin of 28.9%, operating margin of 34.0%, and return on assets of 14.4%, earning a perfect profitability score. Quarterly momentum remained strong through the trailing four quarters, with operating income staying elevated above $1,984,000,000 in every period. The company also maintains a consistent dividend growth track record, raising dividends per share from $2.92 in FY2022 to $3.16 in FY2025 at a moderate 47.0% payout ratio.
Plain English
Gilead had a massive profit comeback in 2025 — its earnings jumped over 16x year-over-year — and it keeps paying a steadily growing dividend, making it look like a solid, mature biotech company with strong financial health.
Bull Case vs. Bear Case
Bull Case
- Net income exploded from $480,000,000 in FY2024 to $8,510,000,000 in FY2025, a gain of +1,672.9%, signaling a powerful bottom-line recovery that dramatically improved earnings quality.
- FY2025 profitability was exceptional across all key metrics: a 28.9% net margin, 34.0% operating margin, and 14.4% return on assets reflect broad-based efficiency and earnings strength.
- Dividends per share have grown every year from $2.92 in FY2022 to $3.16 in FY2025, with a sustainable 47.0% payout ratio, demonstrating consistent capital return to shareholders.
Bear Case
- Top-line revenue growth was only +2.4% in FY2025, rising to $29,443,000,000, suggesting limited organic revenue expansion despite the dramatic profit improvement.
- Quarterly revenue peaked at $7,925,000,000 in 2025Q4 and pulled back to $6,960,000,000 in 2026Q1, indicating some sequential deceleration in the most recent period.
- The theme factor contributed zero points to the composite score despite Gilead's assignment to the Biotech & Genomics macro theme, limiting the overall total.
What Could Change the Picture
Bullish Triggers
- A sustained acceleration in quarterly revenue growth beyond the current +2.4% annual rate would signal that top-line momentum is catching up to the already-strong bottom-line recovery.
- Continued sequential growth in operating income above the $2,586,000,000 level seen in 2026Q1 would reinforce that the earnings recovery is durable rather than transitory.
Bearish Triggers
- A reversal of the net income recovery — for example, net income falling back toward the $480,000,000 FY2024 level — would undermine the core bull thesis built on the FY2025 earnings surge.
- A reduction or pause in dividend growth after four consecutive years of increases would signal deteriorating confidence in future cash generation.
Risk Profile
Low RiskQuarterly revenue showed a pullback from $7,925,000,000 in 2025Q4 to $6,960,000,000 in 2026Q1, introducing some near-term uncertainty about revenue trajectory. However, operating income remained elevated at $2,586,000,000 in 2026Q1, and total assets of $59,023,000,000 provide a substantial balance sheet foundation, supporting the overall Low risk rating.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.